India gives Hetero Labs approval to make Gilead’s COVID-19 drug By Reuters

India gives Hetero Labs approval to make Gilead's COVID-19 drug


© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

(Reuters) – India’s drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science’s experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday.

The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said.

India’s Cipla Ltd (NS:) has also received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug, according to a report https:// in Indian Express.

Cipla and DGCI were not immediately available for comment.

Gilead Sciences Inc (O:) signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its COVID-19 treatment.

The pacts allow Jubilant Life Sciences Ltd (NS:), Cipla, Hetero Labs, Mylan NV (O:) and Ferozsons Laboratories Ltd (PSX:) to make and sell the drug in 127 countries.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME